High-mobility group box-1 and its role in angiogenesis

Journal of Leukocyte Biology

Volumn 95, Issue 4, 2014, Pages 563-574

  Yang, Shuai ^a   Xu, Linxinyu ^a   Yang, Tianshu ^a   Wang, Fang ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytokine; Endothelial cells; RAGE; TLR4

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 4;

ANGIOGENESIS; CYTOKINE RELEASE; HUMAN; INFLAMMATION; ISCHEMIA; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; WOUND HEALING;

CYTOKINE; ENDOTHELIAL CELLS; RAGE; TLR4;

ANIMALS; DIABETIC RETINOPATHY; HMGB1 PROTEIN; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTOR 4; WOUND HEALING;

EID: 84899867933     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0713412     Document Type: Review

References (152)

1. Thomas, J. O., Stott, K. (2012) H1 and HMGB1: modulators of chromatin structure. Biochem. Soc. Trans. 40, 341-346.
2. Thomas, J. O., Travers, A. A. (2001) HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 26, 167-174.
3. Stros, M. (2010) HMGB proteins: interactions with DNA and chromatin. Biochim. Biophys. Acta 1799, 101-113.
4. Yang, H., Antoine, D. J., Andersson, U., Tracey, K. J. (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukoc. Biol. 93, 865-873.
5. Scaffidi, P., Misteli, T., Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
6. Tang, D., Kang, R., Xiao, W., Jiang, L., Liu, M., Shi, Y., Wang, K., Wang, H., Xiao, X. (2007) Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J. Immunol. 178, 7376-7384.
7. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., Coyle, A. J. (2010) HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388.
8. Andersson, U., Tracey, K. J. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162.
9. Huang, W., Tang, Y., Li, L. (2010) HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51, 119-126.
10. Pullerits, R., Urbonaviciute, V., Voll, R. E., Forsblad-D'Elia, H., Carlsten, H. (2011) Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J. Rheumatol. 38, 1523-1525.
11. Tang, D., Kang, R., Zeh III, H. J., Lotze, M. T. (2010) High-mobility group box 1 and cancer. Biochim. Biophys. Acta 1799, 131-140.
12. Hirsiger, S., Simmen, H. P., Werner, C. M., Wanner, G. A., Rittirsch, D. (2012) Danger signals activating the immune response after trauma. Mediators Inflamm. 2012, 315941.
13. Biscetti, F., Ghirlanda, G., Flex, A. (2011) Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration. Curr. Vasc. Pharmacol. 9, 677-681.
14. Lin, Q., Yang, X. P., Fang, D., Ren, X., Zhou, H., Fang, J., Liu, X., Zhou, S., Wen, F., Yao, X., Wang, J. M., Su, S. B. (2011) High-mobility group box-1 mediates Toll-like receptor 4-dependent angiogenesis. Arterioscler. Thromb. Vasc. Biol. 31, 1024-1032.
15. Abu El-Asrar, A. M., Nawaz, M. I., Kangave, D., Abouammoh, M., Mohammad, G. (2012) High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy. Mediators Inflamm. 2012, 697489.
16. Biscetti, F., Straface, G., De Cristofaro, R., Lancellotti, S., Rizzo, P., Arena, V., Stigliano, E., Pecorini, G., Egashira, K., De Angelis, G., Ghirlanda, G., Flex, A. (2010) High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 59, 1496-1505.
17. Sachdev, U., Cui, X., Tzeng, E. (2013) HMGB1 and TLR4 mediate skeletal muscle recovery in a murine model of hindlimb ischemia. J. Vasc. Surg. 58, 460-469.
18. Tang, D., Kang, R., Livesey, K. M., Cheh, C. W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M. E., Tracey, K. J., Zeh III, H. J., Lotze, M. T. (2010) Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881-892.
19. Kang, R., Zeh, H. J., Lotze, M. T., Tang, D. (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18, 571-580.
20. Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., Savitsky, D., Ronfani, L., Akira, S., Bianchi, M. E., Honda, K., Tamura, T., Kodama, T., Taniguchi, T. (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462, 99-103.
21. Yanai, H., Chiba, S., Ban, T., Nakaima, Y., Onoe, T., Honda, K., Ohdan, H., Taniguchi, T. (2011) Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for highmobility group box proteins (HMGBs). Proc. Natl. Acad. Sci. USA 108, 11542-11547.
22. Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., Rubartelli, A. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001.
23. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A., Tracey, K. J. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
24. Qin, S., Wang, H., Yuan, R., Li, H., Ochani, M., Ochani, K., Rosas-Ballina, M., Czura, C. J., Huston, J. M., Miller, E., Lin, X., Sherry, B., Kumar, A., Larosa, G., Newman, W., Tracey, K. J., Yang, H. (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637-1642.
25. Sachdev, U., Cui, X., Hong, G., Namkoong, S., Karlsson, J. M., Baty, C. J., Tzeng, E. (2012) High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J. Vasc. Surg. 55, 180-191.
26. Thorburn, J., Frankel, A. E., Thorburn, A. (2009) Regulation of HMGB1 release by autophagy. Autophagy 5, 247-249.
27. Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., Thorburn, A. (2009) Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16, 175-183.
28. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., Zitvogel, L. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059.
29. Bianchi, M. E. (2009) HMGB1 loves company. J. Leukoc. Biol. 86, 573-576.
30. Lu, B., Nakamura, T., Inouye, K., Li, J., Tang, Y., Lundback, P., Valdes-Ferrer, S. I., Olofsson, P. S., Kalb, T., Roth, J., Zou, Y., Erlandsson-Harris, H., Yang, H., Ting, J. P., Wang, H., Andersson, U., Antoine, D. J., Chavan, S. S., Hotamisligil, G. S., Tracey, K. J. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670-674.
31. Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752-25761.
32. Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A., Abraham, E. (2004) Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377.
33. Ivanov, S., Dragoi, A. M., Wang, X., Dallacosta, C., Louten, J., Musco, G., Sitia, G., Yap, G. S., Wan, Y., Biron, C. A., Bianchi, M. E., Wang, H., Chu, W. M. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981.
34. Chen, G. Y., Tang, J., Zheng, P., Liu, Y. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722-1725.
35. Tang, D., Lotze, M. T. (2012) Tumor immunity times out: TIM-3 and HMGB1. Nat. Immunol. 13, 808-810.
36. Venereau, E., Schiraldi, M., Uguccioni, M., Bianchi, M. E. (2013) HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol. Immunol. 55, 76-82.
37. Orlova, V. V., Choi, E. Y., Xie, C., Chavakis, E., Bierhaus, A., Ihanus, E., Ballantyne, C. M., Gahmberg, C. G., Bianchi, M. E., Nawroth, P. P., Chavakis, T. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26, 1129-1139.
38. Campana, L., Bosurgi, L., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86, 609-615.
39. Yang, H., Lundback, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M. E., Al-Abed, Y., Andersson, U., Tracey, K. J., Antoine, D. J. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18, 250-259.
40. Yang, H., Hreggvidsdottir, H. S., Palmblad, K., Wang, H., Ochani, M., Li, J., Lu, B., Chavan, S., Rosas-Ballina, M., Al-Abed, Y., Akira, S., Bierhaus, A., Erlandsson-Harris, H., Andersson, U., Tracey, K. J. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. USA 107, 11942-11947.
41. Antoine, D. J., Williams, D. P., Kipar, A., Laverty, H., Park, B. K. (2010) Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol. Med. 16, 479-490.
42. Oh, Y. J., Youn, J. H., Ji, Y., Lee, S. E., Lim, K. J., Choi, J. E., Shin, J. S. (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182, 5800-5809.
43. Ito, I., Fukazawa, J., Yoshida, M. (2007) Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282, 16336-16344.
44. Schmidt, A. M., Yan, S. D., Yan, S. F., Stern, D. M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955.
45. Stern, D., Yan, S. D., Yan, S. F., Schmidt, A. M. (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 54, 1615-1625.
46. Chavakis, E., Hain, A., Vinci, M., Carmona, G., Bianchi, M. E., Vajkoczy, P., Zeiher, A. M., Chavakis, T., Dimmeler, S. (2007) High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ. Res. 100, 204-212.
47. Huttunen, H. J., Fages, C., Rauvala, H. (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274, 19919-19924.
48. Rauvala, H., Rouhiainen, A. (2010) Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim. Biophys. Acta 1799, 164-170.
49. Yang, H., Wang, H., Czura, C. J., Tracey, K. J. (2005) The cytokine activity of HMGB1. J. Leukoc. Biol. 78, 1-8.
50. Dumitriu, I. E., Baruah, P., Valentinis, B., Voll, R. E., Herrmann, M., Nawroth, P. P., Arnold, B., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
51. Manfredi, A. A., Capobianco, A., Esposito, A., De Cobelli, F., Canu, T., Monno, A., Raucci, A., Sanvito, F., Doglioni, C., Nawroth, P. P., Bierhaus, A., Bianchi, M. E., Rovere-Querini, P., Del Maschio, A. (2008) Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180, 2270-2275.
52. Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., Oppenheim, J. J. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66.
53. Rouhiainen, A., Kuja-Panula, J., Wilkman, E., Pakkanen, J., Stenfors, J., Tuominen, R. K., Lepantalo, M., Carpen, O., Parkkinen, J., Rauvala, H. (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104, 1174-1182.
54. Riuzzi, F., Sorci, G., Donato, R. (2006) The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem. 281, 8242-8253.
55. van Beijnum, J. R., Buurman, W. A., Griffioen, A. W. (2008) Convergence and amplification of Toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11, 91-99.
56. Miyake, K. (2004) Endotoxin recognition molecules, Toll-like receptor 4-MD-2. Semin. Immunol. 16, 11-16.
57. Yang, H., Lundback, P., Ottosson, L., Al Abed, Y., Ochani, M., Li, J., Lu, B., Chavan, S., Antoine, D., Harris, H. (2012) HMGB11 cysteine 106 is required for binding to MD-2 in the TLR4/MD2 complex to elicit inflammatory responses. Shock 37 (Suppl. 1), 28.
58. Kim, S., Kim, S. Y., Pribis, J. P., Lotze, M., Mollen, K. P., Shapiro, R., Loughran, P., Scott, M. J., Billiar, T. R. (2013) Signaling of high mobility group box 1 (HMGB1) through Toll-like receptor 4 in macrophages requires CD14. Mol. Med. 19, 88-98.
59. Yang, Q. W., Lu, F. L., Zhou, Y., Wang, L., Zhong, Q., Lin, S., Xiang, J., Li, J. C., Fang, C. Q., Wang, J. Z. (2011) HMGB1 mediates ischemiareperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J. Cereb. Blood Flow Metab. 31, 593-605.
60. Kazama, H., Ricci, J-E., Herndon, J. M., Hoppe, G., Green, D. R., Ferguson, T. A. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32.
61. Schiraldi, M., Raucci, A., Munoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., Thelen, M., Varani, L., Mellado, M., Proudfoot, A., Bianchi, M. E., Uguccioni, M. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551-563.
62. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., Shams, S. S., Yang, H., Varani, L., Andersson, U., Tracey, K. J., Bachi, A., Uguccioni, M., Bianchi, M. E. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528.
63. Hreggvidsdottir, H. S., Ostberg, T., Wahamaa, H., Schierbeck, H., Aveberger, A. C., Klevenvall, L., Palmblad, K., Ottosson, L., Andersson, U., Harris, H. E. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86, 655-662.
64. Tian, J., Avalos, A. M., Mao, S-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496.
65. Abu-Amara, M., Yang, S. Y., Tapuria, N., Fuller, B., Davidson, B., Seifalian, A. (2010) Liver ischemia/reperfusion injury: processes in inflammatory networks-a review. Liver Transpl. 16, 1016-1032.
66. Youn, J. H., Oh, Y. J., Kim, E. S., Choi, J. E., Shin, J. S. (2008) High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. J. Immunol. 180, 5067-5074.
67. Urbonaviciute, V., Furnrohr, B. G., Meister, S., Munoz, L., Heyder, P., De Marchis, F., Bianchi, M. E., Kirschning, C., Wagner, H., Manfredi, A. A., Kalden, J. R., Schett, G., Rovere-Querini, P., Herrmann, M., Voll, R. E. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205, 3007-3018.
68. Sha, Y., Zmijewski, J., Xu, Z., Abraham, E. (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180, 2531-2537.
69. Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shelhamer, J. H., Suffredini, A. F. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652-2660.
70. Andersson, U., Wang, H., Palmblad, K., Aveberger, A. C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., Tracey, K. J. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570.
71. Mullins, G. E., Sunden-Cullberg, J., Johansson, A. S., Rouhiainen, A., Erlandsson-Harris, H., Yang, H., Tracey, K. J., Rauvala, H., Palmblad, J., Andersson, J., Treutiger, C. J. (2004) Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand. J. Immunol. 60, 566-573.
72. Van Beijnum, J. R., Nowak-Sliwinska, P., van den Boezem, E., Hautvast, P., Buurman, W. A., Griffioen, A. W. (2013) Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32, 363-374.
73. Tsung, A., Klune, J. R., Zhang, X., Jeyabalan, G., Cao, Z., Peng, X., Stolz, D. B., Geller, D. A., Rosengart, M. R., Billiar, T. R. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204, 2913-2923.
74. Nace, G. W., Huang, H., Klune, J. R., Eid, R. E., Rosborough, B. R., Korff, S., Li, S., Shapiro, R. A., Stolz, D. B., Sodhi, C. P., Hackam, D. J., Geller, D. A., Billiar, T. R., Tsung, A. (2013) Cellular-specific role of Toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology 58, 374-387.
75. Straino, S., Di Carlo, A., Mangoni, A., De Mori, R., Guerra, L., Maurelli, R., Panacchia, L., Di Giacomo, F., Palumbo, R., Di Campli, C., Uccioli, L., Biglioli, P., Bianchi, M. E., Capogrossi, M. C., Germani, A. (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J. Invest. Dermatol. 128, 1545-1553.
76. Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K. J., Bendszus, M., Rossetti, G., Nawroth, P. P., Bierhaus, A., Schwaninger, M. (2008) The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023-12031.
77. Schlueter, C., Weber, H., Meyer, B., Rogalla, P., Roser, K., Hauke, S., Bullerdiek, J. (2005) Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166, 1259-1263.
78. Mitola, S., Belleri, M., Urbinati, C., Coltrini, D., Sparatore, B., Pedrazzi, M., Melloni, E., Presta, M. (2006) Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J. Immunol. 176, 12-15.
79. Kim, W., Moon, S. O., Sung, M. J., Kim, S. H., Lee, S., So, J. N., Park, S. K. (2003) Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J. 17, 1937-1939.
80. Naugler, W. E., Karin, M. (2008) NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26.
81. Dormond, O., Foletti, A., Paroz, C., Ruegg, C. (2001) NSAIDs inhibit α V β 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 7, 1041-1047.
82. De Mori, R., Straino, S., Di Carlo, A., Mangoni, A., Pompilio, G., Palumbo, R., Bianchi, M. E., Capogrossi, M. C., Germani, A. (2007) Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler. Thromb. Vasc. Biol. 27, 2377-2383.
83. Van Beijnum, J. R., Dings, R. P., van der Linden, E., Zwaans, B. M., Ramaekers, F. C., Mayo, K. H., Griffioen, A. W. (2006) Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108, 2339-2348.
84. Nucera, S., Biziato, D., De Palma, M. (2011) The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int. J. Dev. Biol. 55, 495.
85. Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., Wilson, S. W., Ruhrberg, C. (2010) Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGFmediated endothelial tip cell induction. Blood 116, 829-840.
86. Urbich, C., Dimmeler, S. (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95, 343-353.
87. Cossu, G., Bianco, P. (2003) Mesoangioblasts-vascular progenitors for extravascular mesodermal tissues. Curr. Opin. Genet. Dev. 13, 537-542.
88. Minasi, M. G., Riminucci, M., De Angelis, L., Borello, U., Berarducci, B., Innocenzi, A., Caprioli, A., Sirabella, D., Baiocchi, M., De Maria, R., Boratto, R., Jaffredo, T., Broccoli, V., Bianco, P., Cossu, G. (2002) The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129, 2773-2783.
89. Palumbo, R., Sampaolesi, M., De Marchis, F., Tonlorenzi, R., Colombetti, S., Mondino, A., Cossu, G., Bianchi, M. E. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164, 441-449.
90. Hayakawa, K., Pham, L. D., Katusic, Z. S., Arai, K., Lo, E. H. (2012) Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc. Natl. Acad. Sci. USA 109, 7505-7510.
91. Hayakawa, K., Miyamoto, N., Seo, J. H., Pham, L. D., Kim, K. W., Lo, E. H., Arai, K. (2012) High-mobility group box 1 from reactive astrocytes enhances the accumulation of endothelial progenitor cells in damaged white matter. J. Neurochem. 125, 273-280.
92. Mirshahi, F., Pourtau, J., Li, H., Muraine, M., Trochon, V., Legrand, E., Vannier, J., Soria, J., Vasse, M., Soria, C. (2000) SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb. Res. 99, 587-594.
93. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., Weinberg, R. A. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
94. Butler, J. M., Guthrie, S. M., Koc, M., Afzal, A., Caballero, S., Brooks, H. L., Mames, R. N., Segal, M. S., Grant, M. B., Scott, E. W. (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J. Clin. Invest. 115, 86-93.
95. Petit, I., Jin, D., Rafii, S. (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299-307.
96. Jiang, W., Wang, Z., Li, X., Fan, X., Duan, Y. (2012) High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol. Oncol. Res. 18, 293-298.
97. Shang, G. H., Jia, C. Q., Tian, H., Xiao, W., Li, Y., Wang, A. H., Dong, L., Lin, D. J. (2009) Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir. Med. 103, 1949-1953.
98. Kim, J. B., Lim, C. M., Yu, Y. M., Lee, J. K. (2008) Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J. Neurosci. Res. 86, 1125-1131.
99. Chung, H. W., Lee, S. G., Kim, H., Hong, D. J., Chung, J. B., Stroncek, D., Lim, J. B. (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J. Transl. Med. 7, 38.
100. Sheng, X., Du, X., Zhang, X., Li, D., Lu, C., Li, Q., Ma, Z., Song, Q., Wang, C. (2009) Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat. Med. J. 50, 455-464.
101. Yao, X., Zhao, G., Yang, H., Hong, X., Bie, L., Liu, G. (2010) Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J. Cancer Res. Clin. Oncol. 136, 677-684.
102. Ishiguro, H., Nakaigawa, N., Miyoshi, Y., Fujinami, K., Kubota, Y., Uemura, H. (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64, 92-100.
103. Kuniyasu, H., Chihara, Y., Kondo, H., Ohmori, H., Ukai, R. (2003) Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol. Rep. 10, 1863-1868.
104. Hao, Q., Du, X. Q., Fu, X., Tian, J. (2008) Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 30, 292-295.
105. Leek, R. D., Landers, R. J., Harris, A. L., Lewis, C. E. (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79, 991-995.
106. Lee, H., Song, M., Shin, N., Shin, C. H., Min, B. S., Kim, H. S., Yoo, J. S., Kim, H. (2012) Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7, e34318.
107. Cheng, B. Q., Jia, C. Q., Liu, C. T., Lu, X. F., Zhong, N., Zhang, Z. L., Fan, W., Li, Y. Q. (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig. Liver Dis. 40, 446-452.
108. Zhang, J., Zhu, J. S., Zhou, Z., Chen, W. X., Chen, N. W. (2012) Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. Oncol. Rep. 27, 1511-1519.
109. Brezniceanu, M. L., Volp, K., Bosser, S., Solbach, C., Lichter, P., Joos, S., Zornig, M. (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 17, 1295-1297.
110. Shen, X., Hong, L., Sun, H., Shi, M., Song, Y. (2009) The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol. Rep. 22, 535-539.
111. Luo, Y., Ohmori, H., Fujii, K., Moriwaka, Y., Sasahira, T., Kurihara, M., Tatsumoto, N., Sasaki, T., Yamashita, Y., Kuniyasu, H. (2010) HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur. J. Cancer 46, 791-799.
112. Kusume, A., Sasahira, T., Luo, Y., Isobe, M., Nakagawa, N., Tatsumoto, N., Fujii, K., Ohmori, H., Kuniyasu, H. (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76, 155-162.
113. Moriwaka, Y., Luo, Y., Ohmori, H., Fujii, K., Tatsumoto, N., Sasahira, T., Kuniyasu, H. (2010) HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 77, 17-23.
114. Sorensen, M. V., Pedersen, S., Mogelvang, R., Skov-Jensen, J., Flyvbjerg, A. (2011) Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc. Interv. 4, 281-286.
115. Goldstein, R. S., Gallowitsch-Puerta, M., Yang, L., Rosas-Ballina, M., Huston, J. M., Czura, C. J., Lee, D. C., Ward, M. F., Bruchfeld, A. N., Wang, H., Lesser, M. L., Church, A. L., Litroff, A. H., Sama, A. E., Tracey, K. J. (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25, 571-574.
116. Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., Hofmann, M. A., Kislinger, T., Ingram, M., Lu, A., Tanaka, H., Hori, O., Ogawa, S., Stern, D. M., Schmidt, A. M. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354-360.
117. Sasahira, T., Kirita, T., Bhawal, U. K., Ikeda, M., Nagasawa, A., Yamamoto, K., Kuniyasu, H. (2007) The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch. 450, 287-295.
118. Maeda, S., Hikiba, Y., Shibata, W., Ohmae, T., Yanai, A., Ogura, K., Yamada, S., Omata, M. (2007) Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem. Biophys. Res. Commun. 360, 394-400.
119. Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., Pass, H. I., Gaudino, G., Carbone, M., Yang, H. (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290-3301.
120. Pachydaki, S. I., Tari, S. R., Lee, S. E., Ma, W., Tseng, J. J., Sosunov, A. A., Cataldergirmen, G., Scarmeas, N., Caspersen, C., Chang, S., Schiff, W. M., Schmidt, A. M., Barile, G. R. (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 82, 807-815.
121. Abu El-Asrar, A. M., Imtiaz Nawaz, M., Kangave, D., Siddiquei, M. M., Geboes, K. (2012) Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm. 2012, 493043.
122. Abu El-Asrar, A. M., Missotten, L., Geboes, K. (2011) Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Mol. Vis. 17, 508-518.
123. Abu El-Asrar, A. M., Nawaz, M. I., Kangave, D., Geboes, K., Ola, M. S., Ahmad, S., Al-Shabrawey, M. (2011) High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol. Vis. 17, 1829-1838.
124. Singer, A. J., Clark, R. A. (1999) Cutaneous wound healing. N. Engl. J. Med. 341, 738-746.
125. Kohno, T., Anzai, T., Naito, K., Miyasho, T., Okamoto, M., Yokota, H., Yamada, S., Maekawa, Y., Takahashi, T., Yoshikawa, T., Ishizaka, A., Ogawa, S. (2009) Role of high-mobility group box 1 protein in postinfarction healing process and left ventricular remodelling. Cardiovasc. Res. 81, 565-573.
126. Qiu, J., Nishimura, M., Wang, Y., Sims, J. R., Qiu, S., Savitz, S. I., Salomone, S., Moskowitz, M. A. (2008) Early release of HMGB-1 from neurons after the onset of brain ischemia. J. Cereb. Blood Flow Metab. 28, 927-938.
127. Dardenne, A. D., Wulff, B. C., Wilgus, T. A. (2013) The alarmin HMGB-1 influences healing outcomes in fetal skin wounds. Wound Repair Regen. 21, 282-291.
128. Kitahara, T., Takeishi, Y., Harada, M., Niizeki, T., Suzuki, S., Sasaki, T., Ishino, M., Bilim, O., Nakajima, O., Kubota, I. (2008) High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc. Res. 80, 40-46.
129. Semenza, G. L. (2007) Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J. Cell. Biochem. 102, 840-847.
130. Mehta, J., Dhalla, N. S. (2013) Biochemical Basis and Therapeutic Implications of Angiogenesis. Springer, London, New York.
131. Duffy, G. P., Herron, C. C. (2013) Mesenchymal stem cells to augment therapeutic angiogenesis in hind-limb ischemia models: how important is their source? Stem Cell Res. Ther. 4, 131.
132. Fujita, Y., Asahara, T., Kawamoto, A. (2013) Angiogenesis in myocardial ischemia. In Biochemical Basis and Therapeutic Implications of Angiogenesis (Mehta, J. S. DhallaN., eds.), Springer, London, New York, 261-283.
133. Hayakawa, K., Seo, J. H., Miyamoto, N., Pham, L-D.D., Navaratna, D., Lo, E. H., Arai, K. (2013) Brain angiogenesis after stroke. In Biochemical Basis and Therapeutic Implications of Angiogenesis (Mehta, J. S. DhallaN., eds.), Springer, London, New York, 239-260.
134. Vogelgesang, A., May, V. E., Grunwald, U., Bakkeboe, M., Langner, S., Wallaschofski, H., Kessler, C., Broker, B. M., Dressel, A. (2010) Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 5, e8718.
135. Kim, S. W., Jin, Y., Shin, J. H., Kim, I. D., Lee, H. K., Park, S., Han, P. L., Lee, J. K. (2013) Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol. Dis. 46, 147-156.
136. Kim, I. D., Shin, J. H., Lee, H. K., Jin, Y. C., Lee, J. K. (2012) Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci. Lett. 525, 179-183.
137. Kim, I. D., Shin, J. H., Kim, S. W., Choi, S., Ahn, J., Han, P. L., Park, J. S., Lee, J. K. (2012) Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol. Ther. 20, 829-839.
138. Qiu, J., Xu, J., Zheng, Y., Wei, Y., Zhu, X., Lo, E. H., Moskowitz, M. A., Sims, J. R. (2010) High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 41, 2077-2082.
139. Hayakawa, K., Mishima, K., Irie, K., Hazekawa, M., Mishima, S., Fujioka, M., Orito, K., Egashira, N., Katsurabayashi, S., Takasaki, K., Iwasaki, K., Fujiwara, M. (2008) Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55, 1280-1286.
140. Wang, Q., Wang, F., Li, X., Yang, Q., Li, X., Xu, N., Huang, Y., Zhang, Q., Gou, X., Chen, S., Xiong, L. (2012) Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats. J. Neuroinflammation. 9, 24.
141. Zhang, J., Takahashi, H. K., Liu, K., Wake, H., Liu, R., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Mori, S., Nishibori, M. (2011) Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42, 1420-1428.
142. Kikuchi, K., Kawahara, K., Biswas, K. K., Ito, T., Tancharoen, S., Morimoto, Y., Matsuda, F., Oyama, Y., Takenouchi, K., Miura, N., Arimura, N., Nawa, Y., Meng, X., Shrestha, B., Arimura, S., Iwata, M., Mera, K., Sameshima, H., Ohno, Y., Maenosono, R., Yoshida, Y., Tajima, Y., Uchikado, H., Kuramoto, T., Nakayama, K., Shigemori, M., Hashiguchi, T., Maruyama, I. (2009) Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced cell death in ischemic neuronal injury in PC12 cells. Biochem. Biophys. Res. Commun. 385, 132-136.
143. Ding, H. S., Yang, J., Gong, F. L., Yang, J., Ding, J. W., Li, S., Jiang, Y. R. (2012) High mobility group box 1 mediates neutrophil recruitment in myocardial ischemia-reperfusion injury through Toll like receptor 4-related pathway. Gene 509, 149-153.
144. Andrassy, M., Volz, H. C., Igwe, J. C., Funke, B., Eichberger, S. N., Kaya, Z., Buss, S., Autschbach, F., Pleger, S. T., Lukic, I. K., Bea, F., Hardt, S. E., Humpert, P. M., Bianchi, M. E., Mairbaurl, H., Nawroth, P. P., Remppis, A., Katus, H. A., Bierhaus, A. (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117, 3216-3226.
145. Xu, H., Yao, Y., Su, Z., Yang, Y., Kao, R., Martin, C. M., Rui, T. (2011) Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am. J. Physiol. Heart Circ. Physiol. 300, H913-H921.
146. Zhai, C. L., Zhang, M. Q., Zhang, Y., Xu, H. X., Wang, J. M., An, G. P., Wang, Y. Y., Li, L. (2012) Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol. Sin. 33, 1477-1487.
147. Zhu, H., Li, J., Wang, S., Liu, K., Wang, L., Huang, L. (2013) HMGB1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation 95, 1448-1454.
148. Hu, X., Cui, B., Zhou, X., Xu, C., Lu, Z., Jiang, H. (2012) Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol. Biol. Rep. 39, 227-231.
149. Hu, X., Zhou, X., He, B., Xu, C., Wu, L., Cui, B., Wen, H., Lu, Z., Jiang, H. (2010) Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur. J. Pharmacol. 638, 84-89.
150. Andrassy, M., Volz, H. C., Riedle, N., Gitsioudis, G., Seidel, C., Laohachewin, D., Zankl, A. R., Kaya, Z., Bierhaus, A., Giannitsis, E., Katus, H. A., Korosoglou, G. (2011) HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J. Intern. Med. 270, 245-253.
151. Liu, K., Mori, S., Takahashi, H. K., Tomono, Y., Wake, H., Kanke, T., Sato, Y., Hiraga, N., Adachi, N., Yoshino, T., Nishibori, M. (2007) Antihigh mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 21, 3904-3916.
152. de Souza, A. W., Westra, J., Limburg, P. C., Bijl, M., Kallenberg, C. G. (2012) HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun. Rev. 11, 909-917.